Abstract
Optimal management of duodenal neuroendocrine tumors (DNETs) has not been well-defined, especially for DNETs 1–2 cm in size. Recent studies comparing endoscopic mucosal resection (EMR) and surgical resection demonstrate EMR is safe and effective for these intermediate-sized DNETs. Expert and consensus guidelines could consider updating recommendations to reflect the outcomes of EMR in DNETs and the importance of endoscopic surveillance in these patients to evaluate for local recurrence.
References
Gay-Chevallier S, de Mestier L, Perinel J, et al. Management and prognosis of localized duodenal neuroendocrine neoplasms. Neuroendocrinology. 2021;111(8):718–27.
Mahmud N, Tomizawa Y, Stashek K, Katona BW, Ginsberg GG, Metz DC. Endoscopic resection of duodenal carcinoid tumors: a single-center comparison between simple polypectomy and endoscopic mucosal resection. Pancreas. 2019;48(1):60–5.
Delle Fave G, O’Toole D, Sundin A, et al. ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24.
Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw. 2018;16(6):693–702.
Tran CG, Sherman SK, Suraju MO, et al. Management of duodenal neuroendocrine tumors: surgical versus endoscopic mucosal resection. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-10774-9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tran, C.G., Sherman, S.K. & Howe, J.R. ASO Author Reflections: Endoscopic Management is Reasonable for <2 cm Duodenal Neuroendocrine Tumors. Ann Surg Oncol 29, 85–86 (2022). https://doi.org/10.1245/s10434-021-10859-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-10859-5